| Nailike (olverembatinib) / Ascentage Pharma, Takeda |
ChiCTR1900027568: Phase I Dose Escalation and Expansion Study of HQP1351 on Tyrosine Kinase Inhibitor (TKI) Resistant Patients with Chronic Myelogenous Leukemia |
|
|
| Recruiting | 1 | 105 | | HQP1351 orally, once every other day(QOD) for consecutive 4 weeks each cycle. ;HQP1351 orally, once every other day(QOD) for consecutive 4 weeks each cycle. ;HQP1351 orally, once every other day(QOD) for consecutive 4 weeks each cycle. ;HQP1351 orally, once every other day(QOD) for consecutive 4 weeks each cycle. ;HQP1351 orally, once every other day(QOD) for consecutive 4 weeks each cycle. ;HQP1351 orally, once every other day(QOD) for consecutive 4 weeks each cycle. ;HQP1351 orally, once every other day(QOD) for consecutive 4 weeks each cycle. ;HQP1351 orally, once every other day(QOD) for consecutive 4 weeks each cycle. ;HQP1351 orally, once every other day(QOD) for consecutive 4 weeks each cycle. ;HQP1351 orally, once every other day(QOD) for consecutive 4 weeks each cycle. ;HQP1351 orally, once every other day(QOD) for consecutive 4 weeks each cycle. | Peking University People's Hospital; Health Quest Pharma Inc., Health Quest Pharma Inc. | Chronic Myelogenous Leukemia | | | | |
| Recruiting | 1 | 62 | US | Ascentage Pharma HQP1351 bioavailable inhibitor, Blinatumomab, Blincyto | Ascentage Pharma Group Inc. | Leukemia, Myeloid, Chronic, Myeloid Leukemia, Chronic Myeloid Leukemia, Philadelphia Positive Acute Lymphoblastic Leukemia, B Cell Precursor Type Acute Leukemia | 01/24 | 01/24 | | |
NCT05495035: Study for Safety and Efficacy of Olverembatinib Combined With APG-2575 in Children With Relapsed/Refractory Ph + ALL |
|
|
| Recruiting | 1 | 22 | RoW | Olverembatinib, APG-2575, Dexamethasone | Institute of Hematology & Blood Diseases Hospital | Lymphoblastic Leukemia, Acute, Childhood, Leukemia, Lymphoblastic, Acute, Philadelphia-Positive, Relapsed Leukemia, Refractory Leukemia | 08/24 | 12/24 | | |
NCT06401603: A Phase I Study of Decitabine, Lisaftoclax, and Olverembatinib in Patients With Advanced Chronic Myeloid Leukemia and Philadelphia Chromosome-Positive Acute Myeloid Leukemia |
|
|
| Not yet recruiting | 1 | 30 | US | Decitabine, Dacogen, Listaftoclax, Olverembatinib | M.D. Anderson Cancer Center, Ascentage Pharma Group Inc. | Advanced Chronic Myeloid Leukemia, Philadelphia Chromosome-Positive Acute Myeloid Leukemia | 01/27 | 01/29 | | |
| Recruiting | 1 | 100 | RoW | HQP1351 | Ascentage Pharma Group Inc., HealthQuest Pharma Inc. | Gastrointestinal Stromal Tumor (GIST), Solid Tumor, Adult | 12/24 | 12/26 | | |
